Literature DB >> 16689554

Data mining in the US using the Vaccine Adverse Event Reporting System.

John Iskander1, Vitali Pool, Weigong Zhou, Roseanne English-Bullard.   

Abstract

The US Vaccine Adverse Event Reporting System (VAERS), which is charged with vigilance for detecting vaccine-related safety issues, faces an increasingly complex immunisation environment. Since 1990, steady increases in vaccine licensing and distribution have resulted in increasing numbers of reports to VAERS. Prominent features of current reports include more routine vaccine co-administration and frequent reports of new postvaccination clinical syndromes. Data-mining methods, based on disproportionality analyses, are one strategy being pursued by VAERS researchers to increase the utility of its complex database. The types of analyses used include proportional reporting ratios, association rule discovery, and various 'historic limits' methods that compare observed versus expected event counts. The use of such strategies in VAERS has been primarily supplemental and retrospective. Signals for inactivated influenza, typhoid and tetanus toxoid-containing vaccines have been successfully identified. Concerns flagged through data mining should always be subject to clinical case review as a first evaluation step. Persistent issues should be subject to formal hypothesis testing in large linked databases or other controlled-study settings. Automated data-mining techniques for prospective use are currently undergoing development and evaluation within VAERS. Their use (as one signal-detection tool among many) by trained medical evaluators who are aware of system limitations is one legitimate approach to improving the ability of VAERS to generate vaccine-safety hypotheses. Such approaches are needed as more new vaccines continue to be licensed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689554     DOI: 10.2165/00002018-200629050-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  57 in total

1.  Detection of adverse events: what are the current sensitivity limits during clinical development?

Authors:  B Fritzell
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

2.  The power of 'box a'.

Authors:  Paul A Offit
Journal:  Expert Rev Vaccines       Date:  2003-02       Impact factor: 5.217

3.  Suspension of rotavirus vaccine after reports of intussusception--United States, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-09-03       Impact factor: 17.586

Review 4.  Principles of signal detection in pharmacovigilance.

Authors:  R H Meyboom; A C Egberts; I R Edwards; Y A Hekster; F H de Koning; F W Gribnau
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

5.  Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics Committee on Infectious Diseases.

Authors: 
Journal:  Pediatrics       Date:  1995-05       Impact factor: 7.124

6.  Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Authors:  Vitali Pool; M Miles Braun; John M Kelso; Gina Mootrey; Robert T Chen; John W Yunginger; Robert M Jacobson; Paul M Gargiullo
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

7.  Using data mining to characterize DNA mutations by patient clinical features.

Authors:  S Evans; S J Lemon; C Deters; R M Fusaro; C Durham; C Snyder; H T Lynch
Journal:  Proc AMIA Annu Fall Symp       Date:  1997

Review 8.  Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000.

Authors:  N A Halsey; S L Hyman
Journal:  Pediatrics       Date:  2001-05       Impact factor: 7.124

9.  Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.

Authors:  Thomas Verstraeten; Robert L Davis; Frank DeStefano; Tracy A Lieu; Philip H Rhodes; Steven B Black; Henry Shinefield; Robert T Chen
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

10.  A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Authors:  Weigong Zhou; Vitali Pool; Frank DeStefano; John K Iskander; Penina Haber; Robert T Chen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

View more
  9 in total

Review 1.  Influenza immunization during pregnancy: Benefits for mother and infant.

Authors:  Isaac G Sakala; Yoshikazu Honda-Okubo; Johnson Fung; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

2.  A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States.

Authors:  David A Geier; Brian S Hooker; Janet K Kern; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  Transl Neurodegener       Date:  2013-12-19       Impact factor: 8.014

3.  Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.

Authors:  David Martin; David Menschik; Marthe Bryant-Genevier; Robert Ball
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.228

4.  A probabilistic model for reducing medication errors.

Authors:  Phung Anh Nguyen; Shabbir Syed-Abdul; Usman Iqbal; Min-Huei Hsu; Chen-Ling Huang; Hsien-Chang Li; Daniel Livius Clinciu; Wen-Shan Jian; Yu-Chuan Jack Li
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

5.  Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis.

Authors:  Jiangan Xie; Christopher Codd; Kevin Mo; Yongqun He
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

6.  Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.

Authors:  Congqin Chen; Fang Fu; Lingqing Ding; Jie Fang; Jie Xiao
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

7.  A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disorders.

Authors:  David A Geier; Brian S Hooker; Janet K Kern; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  Int J Environ Res Public Health       Date:  2014-09-05       Impact factor: 3.390

8.  Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  N Am J Med Sci       Date:  2014-10

9.  Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Lisa K Sykes; Mark R Geier
Journal:  Brain Sci       Date:  2016-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.